A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.

Trial Profile

A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs GSK 1674330A (Primary) ; AS01E; AS02; AS04A; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Mar 2014 Primary endpoint 'Geometric-mean-antibody-titre' has not been met.
    • 24 Mar 2014 Results published in Vaccine.
    • 05 May 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top